Xeris Biopharma Holdings (XERS) Income from Continuing Operations (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Income from Continuing Operations came in at 2234000.0 in Q1 2026, up 124.23% YoY from 996298.73 in Q1 2025, and down 79.84% on a QoQ basis from 11081000.0 in Q4 2025.
Xeris Biopharma Holdings (XERS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Income from Continuing Operations data on file, last reported at 2234000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 124.23% year-over-year to 2234000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12008000.0 (up 126.64% YoY) and the FY2025 annual result came in at 554000.0, up 101.01% from the prior year.
- Income from Continuing Operations declined to 2234000.0 in Q1 2026, from 11081000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11081000.0 in Q4 2025 to a low of 33714000.0 in Q1 2022.
- A 5-year average of 12291941.18 and a median of 13390000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 83.12% — and 2025, when it surged 316.72%.
- Tracing XERS's Income from Continuing Operations over 5 years: stood at 12930000.0 in 2022, then decreased by 3.56% to 13390000.0 in 2023, then soared by 61.81% to 5113000.0 in 2024, then surged by 316.72% to 11081000.0 in 2025, then tumbled by 79.84% to 2234000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2234000.0 (Q1 2026), 11081000.0 (Q4 2025), and 621000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | -31.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.10 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 11.08 Mn |
| Sep 30, 2025 | 621,000.00 |
| Jun 30, 2025 | -1.93 Mn |
| Mar 31, 2025 | -9.22 Mn |
| Dec 31, 2024 | -5.11 Mn |
| Sep 30, 2024 | -15.74 Mn |
| Jun 30, 2024 | -15.01 Mn |
| Mar 31, 2024 | -18.98 Mn |
| Dec 31, 2023 | -13.39 Mn |
| Sep 30, 2023 | -12.19 Mn |
| Jun 30, 2023 | -19.84 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -12.93 Mn |
| Sep 30, 2022 | -21.83 Mn |
| Jun 30, 2022 | -26.19 Mn |
| Mar 31, 2022 | -33.71 Mn |
| Dec 31, 2021 | -50.79 Mn |
| Sep 30, 2021 | -26.01 Mn |